Drug Discovery World

FEBRUARY 16, 2024

Dermot Tierney, Chief Operating Officer and Co-Founder, said: “As a drug discovery studio which discovers and develops de novo first-in-class drug candidates for downstream out-licensing this funding will significantly enhance our pipeline of license-ready assets.” in a full seed funding round in the second quarter of 2024.

Disease 147

Disease Licensing Licensing Therapies 147

Drug Discovery World

JANUARY 25, 2024

billion in equity financings, down only 9% from 2022. Major licensing and M&A deals demonstrate the ongoing quality and attractiveness of UK science. The key findings of the new report: UK biotechs secured £1.8 UK retains the top spot in Europe, receiving 41% of total venture capital invested into biotechs across the region.

Licensing 130

Licensing Licensing Science Clinical Trials 130

The Pharma Data

JUNE 14, 2023

In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. billion euros. R&D expenses before special items amounted to 6.2

Licensing 40

Licensing Licensing Small Molecule Science 40

Drug Discovery Today

NOVEMBER 11, 2022

Stockholm, Sweden, November 8, 2022 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.

Licensing 100

Licensing Licensing Drugs Research 100

Drug Discovery World

JANUARY 3, 2023

In November 2022, the EMA granted accelerated assessment for talquetamab, which reduces the timeframe for an MAA to be reviewed. . The application to the EMA follows a Biologics License Application (BLA) submitted to the US Food and Drug Administration (FDA) in December 2022 seeking approval of talquetamab for the treatment of RRMM. . .

Licensing 130

Licensing Licensing Drugs Treatment 130

Drug Discovery World

MAY 29, 2024

Clarify whether mid-level scientists who are eager to license or acquire the assets and leading the discussions still need to clear the case with a senior executive who may not be that interested in it. Success is a bigger pie for both sides The factors above all played a role in the deal which led to Bonum’s launch in November 2022.

International 147

International Licensing Licensing Regulations 147

Drug Discovery World

APRIL 11, 2024

The drug has been licensed in the UK since 2022 as a monotherapy for treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer following prior platinum-based chemotherapy. The decision by the SMC follows final draft guidance by the National Institute for Health and Care Excellence (NICE).

Therapies 130

Therapies Licensing Licensing Treatment 130

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Top-line results are expected in the first half of 2022. ProQR – Netherlands-based ProQR Therapeutics N.V.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52

Drug Discovery World

JUNE 1, 2023

The study forecast growth to 2022 and presented an in-depth strategic assessment of the antibody-drug conjugates, highlighting a number of influencing factors impacting or reinforcing market environment, including government policy, technological changes, and market drivers 4.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

JANUARY 3, 2023

AstraZeneca has initiated the SUPERNOVA Phase I/III trial of AZD5156 (a combination of AZD3152 and cilgavimab) in pre-exposure prophylaxis of Covid-19, following the company licensing AZD3152 from RQ Bio in May 2022. .

Immune Response 130

Immune Response Clinical Trials Vaccine Licensing 130

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in January 2022.

Licensing 52

Licensing Licensing Vaccine FDA 52

Science Daily: Pharmacology News

AUGUST 9, 2023

The drug tecovirimat is currently in use for the treatment of mpox -- the disease caused by monkeypox virus -- that spread worldwide in 2022. Tecovirimat is an anti-poxviral drug, and its use is driving the emergence of drug-resistant variants of the monkeypox virus.

Licensing 47

Licensing Licensing Treatment Virus 47

Drug Discovery World

AUGUST 12, 2022

If the Phase III trial is successful, Pfizer aims to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2025. . April 2022. link] Accessed: July 2022. . February 2022. Official comments .

Vaccine 130

Vaccine Disease Trials Pharmaceutical Companies 130

Drug Discovery World

JANUARY 15, 2024

For an additional $28 million, Lantheus has obtained an option to exclusively license Perspective’s neuroendocrine tumours treatment Pb212-VMT-⍺-NET, or to co-develop certain early stage therapeutic candidates targeting prostate cancer. of Perspective’s shares for up to $33 million.

Targeted Protein Degradation 147

Targeted Protein Degradation Small Molecule Drugs Licensing 147

Drug Discovery World

FEBRUARY 22, 2023

Sustained and durable effect The European Commission’s decision follows the CHMP’s positive opinion in December 2022, based on findings from the pivotal HOPE-B trial, the largest gene therapy trial in haemophilia B to date. The treatment was approved by the US Food and Drug Administration in November 2022.

Therapies 130

Therapies Clinical Trials Licensing Licensing 130

Drug Discovery World

NOVEMBER 14, 2023

billion by 2031, growing at a CAGR of 7% from 2022 to 2031 2 , but is also reflected in data by The Antibody Society, which shows that of the over 100 approved mAbs, around 40% are for cancer 3. billion in 2022 to $53.81 This is not only made clear by the fact that the global cancer mAbs market size was valued at $55.6

Disease 147

Disease FDA Approval Treatment FDA 147

Drug Discovery World

MAY 3, 2023

This financing will enable us to ensure a broad development program of our lead asset uPARAP and further advance our 2nd first-in-class ADC pipeline asset.”

Licensing 130

Licensing Licensing Clinical Development Therapies 130

Drug Discovery World

SEPTEMBER 16, 2022

The therapy is already licensed in the UK for adults and children aged six to 18, and was approved by the FDA in June 2022 for use in younger children.

Therapies 130

Therapies Licensing Licensing Clinical Research 130

Drug Discovery World

JULY 13, 2023

The rules and regulations Unlicensed drugs are drugs that have not yet been assessed by a regulator, while off-label use is when an approved medication is prescribed outside of the terms of its license, e.g., for a different disease or in a different patient group. What are the risks?

Drugs 237

Drugs Licensing Licensing Regulations 237

The Pharma Data

DECEMBER 13, 2020

The FDA also recommended that Gamida Cell generate additional manufacturing-related data prior to requesting a pre-Biologics License Application (BLA) meeting. The revised plan could support a potential commercial launch of omidubicel in the United States as early as mid-2022.

Licensing 52

Licensing Licensing Clinical Trials FDA 52

Drug Discovery World

NOVEMBER 24, 2023

This means durvalumab was granted intellectual property (IP) and included in the Innovative Licensing and Access Pathway (ILAP), which aims to reduce the time it takes innovative treatments to be made available to NHS patients. Innovative Licensing and Access Pathway. 6 Initial data reported a median overall survival of 12.8

Therapies 130

Therapies Licensing Licensing Treatment 130

Drug Discovery World

AUGUST 23, 2022

If approved, ASTX727 would be the first and only oral hypomethylating agent licensed in the European Economic Area (EEA) for the initial treatment of adults with AML who are ineligible for intensive chemotherapy, offering a potentially more convenient treatment regimen. . Abstract P573.

Treatment 130

Treatment Pharmacokinetics Clinical Trials DNA 130

Drug Discovery World

NOVEMBER 21, 2022

The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for anti-CD3-directed antibody TZIELD (teplizumab-mzwv), the first immunomodulatory treatment for type 1 diabetes (T1D). . TZIELD leads to an increase in the proportion of regulatory T cells and exhausted CD8+ T cells in peripheral blood.”

FDA Approval 130

FDA Approval FDA Therapies Disease 130

Drug Discovery World

APRIL 20, 2023

2022, doi: 10.1016/S2215-0366(22)00260-7. 2022, doi: 10.1016/j.euroneuro.2022.04.004. 2022, doi: 10.1038/s41586-022-04569-5. 2022, doi: 10.1016/j.cell.2022.06.008. link] uploads/2022/07/UKCDR-071122- Tracker-Highlights-Long-Covid.pdf (accessed Nov. link] (accessed Nov. Elsevier Inc., 1277–1279, Nov. 2022.07.017.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

Drug Discovery World

JULY 2, 2024

Mazzetti and Schneider continue: “The transfer of technologies from the lab to the market, especially in the field of life sciences is no longer purely via IP out licensing, but rather via start-up M&A deals – start-ups being the de-risking vehicle for large corporates, especially in the life sciences and biotherapeutics sector.

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Channels

FEBRUARY 21, 2023

addresses the Inflation Reduction Act of 2022. There are 241 exhibits in the 2023 edition, compared with 216 in the 2022 edition. If you have any questions before purchasing a license to the report, please email me. A new Section 12.5. In Subsection 12.5.1., In Subsection 12.5.2., Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmacy 97

Pharmacy Specialty Pharmacies Licensing Licensing 97

Drug Discovery World

FEBRUARY 1, 2023

It is estimated that there will be 340,000 medicinal cannabis users in Europe in 2022 alone, and the overall market is estiated to grow over 500% over the next three years – with the market value in Germany alone poised to hit over €7 billion by 2027 1. Portugal is home to Tilray and 19 other licensed pharmaceutical cannabis facilities.

Clinical Trials 130

Clinical Trials Trials Pharmaceutical Companies Doctors 130

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The Phase II trial is fully enrolled and primary data are expected in the fourth quarter of 2022. . “We

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

The Pharma Data

MARCH 25, 2022

Food and Drug Administration (FDA) has extended the review of the supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion-dependent (NTD) beta thalassemia to June 27, 2022. Bristol Myers Squibb (NYSE: BMY) today announced that the U.S.

Licensing 52

Licensing Licensing Drugs FDA 52

Drug Hunter

JUNE 25, 2023

This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, and brain-penetrant HER2 and ROCK2 inhibitors.

Targeted Protein Degradation 130

Targeted Protein Degradation Computational Chemistry Licensing Licensing 130

Drug Discovery World

FEBRUARY 9, 2023

This means durvalumab is eligible for inclusion in the Innovative Licensing and Access Pathway (ILAP). Presented at the 2022 ESMO Virtual Plenary Session, 16–18 March 2022. The MHRA has been a Project Orbis partner since 1 January 2021. 4 Updated median OS was 12.9 months compared to 11.3 months with chemotherapy alone.3

Treatment 130

Treatment Clinical Research International FDA 130

Drug Discovery World

MARCH 7, 2023

In its ‘Women in Business 2022’ report, Grant Thornton reported that at 39%, the healthcare industry had the highest proportion of women in senior management out of the 15 industries surveyed. She has also been awarded the 2022 Liverpool Women In Business, Woman of the year Award.

International 246

International Science Pharmaceuticals DNA 246

Drug Discovery World

AUGUST 31, 2022

The company updated its stance in March 2022 when supply was less of a barrier in parts of the world. However, it expected other companies to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets. Official comments.

Vaccine 130

Vaccine RNA Licensing Licensing 130

Drug Discovery World

AUGUST 3, 2023

Even still, these approved drug products require a licensed healthcare provider’s prescription. 11 The Cannabis Scientist’s Power List 2022 A resource which spotlights the research being undertaken regarding cannabis is The Cannabis Scientist’s Power List 2022, which has been compiled annually since its inception in 2020 12.

Clinical Trials 130

Clinical Trials Regulations Production FDA 130

Drug Discovery World

FEBRUARY 20, 2023

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, according to a recent report by analytics company Phesi. Here, we take a look at the top four disease areas and some of the key developments in 2022. Capivasertib could offer a completely new treatment option for these patients.

Trials 130

Trials Drug Trials Disease Clinical Trials 130

Translation

SEPTEMBER 5, 2023

The Act proposes a significant shift in the way federally-funded inventions are licensed, pressuring entities that receive federal funding to exclusively license new products to American manufacturers. are likely to have a licensing advantage. federally funded lab.

Licensing 40

Licensing Licensing International Production 40

Drug Discovery World

AUGUST 21, 2023

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia. In February 2022, a Danish study showed that the dementia rate was lower in patients randomised to GLP-1 RAs versus placebo.

Clinical Trials 130

Clinical Trials Trials Treatment Licensing 130